Page last updated: 2024-10-15

25-deacetylrifampicin

Description

25-deacetylrifampicin: main metabolite of rifampin in biological fluids; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135889898
MeSH IDM0101133

Synonyms (7)

Synonym
16783-99-6
25-deacetylrifampicin
25-o-deacetyl-3-[(e)-[(4-methyl-1-piperazinyl)imino]methyl]rifamycin
25-desacetylrifampin
25-desacetyl rifampicin
J-010398
Q27284245

Pharmacokinetics

ExcerptReference
" The same applies to the Cmax value (1."( Pharmacokinetic studies of rifampicin in the elderly.
Advenier, C; Bidet, D; Gobert, C; Houin, G; Richelet, S; Tillement, JP, 1983
)
" Pharmacokinetic variables for rifampin determined using the HPLC method were comparable to variables reported from earlier studies utilizing a microbiological assay."( Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares.
Kohn, CW; Kowalski, JJ; Powers, J; Sams, R; Wallace, S, 1993
)
"In the bioavailability studies with drugs biotransformed to biologically active metabolities only the concentrations of the parent drug (PD) are usually taken into account even when the pharmacokinetic data on the metabolite(s) (M) are available."( [Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic].
Dombrovskiĭ, VS; Firsov, AA; Gagaeva, EV; Kadenatsi, IB; Strachunskiĭ, LS, 1996
)

Bioavailability

ExcerptReference
" The bioavailability of the active, orally administered rifampicin decreased from 93% after the first single oral dose to 68% after 3 weeks of oral and intravenous rifampicin therapy."( Pharmacokinetics of oral and intravenous rifampicin during chronic administration.
Eichelbaum, M; Jensen, JC; Loos, U; Mikus, G; Musch, E; Schwabe, HK, 1985
)
"In the bioavailability studies with drugs biotransformed to biologically active metabolities only the concentrations of the parent drug (PD) are usually taken into account even when the pharmacokinetic data on the metabolite(s) (M) are available."( [Correlation between pharmacokinetic parameters of rifampicin and its biologically active metabolite as related to estimation of the relative bioavailability of the antibiotic].
Dombrovskiĭ, VS; Firsov, AA; Gagaeva, EV; Kadenatsi, IB; Strachunskiĭ, LS, 1996
)
"To evaluate the comparative bioavailability of antituberculosis drugs in FDC formulations and the same doses in separate formulations of antituberculosis drugs, using a simplified protocol developed by the World Health Organization (WHO)."( The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
Kaul, CL; Kaur, KJ; Panchagnula, R; Singh, I, 1999
)

Dosage Studied

ExcerptReference
" Simulation of plasma concentrations after different dosage regimens shows that a double rate of infusion--20 mg min-1 during 1 h and then 200 mg h-1--allows plasma concentrations to be quickly reached and maintained at a 20 mg L-1 level, far higher than the minimum inhibitory concentrations of most germs."( Pharmacokinetics of rifampicin and desacetylrifampicin in tuberculous patients after different rates of infusion.
Beucler, A; Brioude, R; Houin, G; Lafaix, C; Richelet, S; Tillement, JP, 1983
)
" administration, we concur with the current dosage recommendation of 10 mg/kg twice a day by mouth."( Pharmacokinetics of single intravenous and single and multiple dose oral administration of rifampin in mares.
Kohn, CW; Kowalski, JJ; Powers, J; Sams, R; Wallace, S, 1993
)
" More research is needed to determine well-founded dosing guidelines."( Pharmacokinetics of intravenous rifampicin (rifampin) in neonates.
Degraeuwe, PL; Neef, C; Pullen, J; Stolk, LM; van Tiel, FH; Zimmermann, LJ, 2006
)
" We determined peak concentration ranges for each drug and acetylisoniazid/isoniazid and 25-desacetylrifampicin/rifampicin ratios by analyzing 2-h post-dose samples in patients treated with standard dosing as a first-line treatment."( Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry.
Jun, SH; Kim, JQ; Lee, JH; Park, KU; Song, J; Song, SH; Yoon, Y, 2007
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (29)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (44.83)18.7374
1990's7 (24.14)18.2507
2000's4 (13.79)29.6817
2010's5 (17.24)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (3.33%)4.05%
Observational0 (0.00%)0.25%
Other24 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]